UNSPSC 51342601: Amidapsone

This classification denotes an antiviral agent and antimicrobial with the molecular formula C13H13N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8N5BE1I42E, chemically known as urea, (p-sulfanilylphenyl)- (8ci) but generally known as amidapsone, which bears US NIH Compound Identifier 66267. European Medicines Agency schedules Amidapsone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05426MIG.

UNSPSC 51342601 Amidapsone is a Commodity code that in recent state and local solicitations covers pharmaceutical supply and emergency-response drug procurement. The actual work being bought under this code diverges significantly from the code's nominal scope: recent opportunities tag Naloxone, Doxycycline, and Ciprofloxacin—not Amidapsone specifically—suggesting the code serves as a catch-all for pharmaceutical warehouse and emergency-drug distribution contracts rather than a product-specific line item. State and local health departments and county community health programs are the primary issuing bodies, procuring pharmaceuticals for public-health emergencies, epidemic response, and standing clinical inventories through both piggyback cooperative-purchasing vehicles and direct competitive bidding.

Recent activity includes an Illinois Department of Public Health award through the MMCAP Infuse consortium to Chartwell Rx LLC (completed August 28, 2026) for antibiotic supply totaling $2,999,999.11 over three years, and a Seminole County, Florida IFB (posted June 30, 2026, response due July 26, 2023) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for delivery to its community health facility. Both solicitations emphasize quarterly or scheduled delivery cycles, E-Verify compliance, and insurance requirements; the Seminole County procurement explicitly names FEMA as a potential funding source and includes federal compliance riders. Activity concentrates in Florida and Illinois, with broader Midwest and Southeast participation likely driven by opioid-response programs and public-health stockpiling mandates.